Agoracom Blog Home

Posts Tagged ‘psilocybin’

Mota Ventures $MOTA.ca Signs Letter of Intent to Acquire German Leader in Psilocybin Space with a 110,000 Square Foot Manufacturing Facility $APH.ca $GBLX $PFE $ACG.ca $ACB.ca $WEED.ca $HIP.ca $WMD.ca $CGRW

Posted by AGORACOM-Eric at 7:49 AM on Thursday, May 14th, 2020
https://s3.amazonaws.com/s3.agoracom.com/public/companies/logos/564664/hub/MOTA_Large.png

VANCOUVER, BC / ACCESSWIRE / May 14, 2020 /Mota Ventures Corp. (CSE:MOTA)(FSE:1WZ:GR)(OTC PINK:PEMTF) (the “Company“) announces that it has entered into a letter of intent (the “Letter of Intent“), dated May 11, 2020, with Verrian Ontario Ltd. (“Verrian“), pursuant to which the parties intend to evaluate a potential transaction involving the acquisition of all of the outstanding share capital of Verrian (the “Proposed Transaction“). Verrian is an arms’-length privately-held company that is focused on delivering and developing products related to addiction reduction, with a focus on alcohol and opiates.

ESTABLISHED EUROPEAN PSYCHEDELIC MEDICINE COMPANY

Verrian owns and operates an EU-GMP, ISO 14001 compliant 110,000 sq. ft. pharmaceutical manufacturing facility in Radebuel, Germany. Verrian purchased the facility from a major global pharmaceutical manufacturer in 2019. Both the facility and equipment are independently appraised at Cdn$10,600,000, including an analytical laboratory, and full pharmaceutical manufacturing suite.

Operations within this full suite pharmaceutical manufacturing site include analytical laboratory and finished dose manufacturing, which exceed all international quality standards.

Verrian is composed of three distinct business segments:

  • Pharmaceutical Manufacturing – A portfolio of medical & wellness products
  • Phyto API – API creation from medical plants
  • Analytical Testing – European Medicine Agency Standards

PRODUCTS FOCUSED ON OPIATE ADDICTION REDUCTION

Verrian’s singular focus is rewiring the mind to overcome addiction through natural medicine. Specifically, the micro dosing of psilocybin demonstrates potential to remove the dopamine reward of addictive substances, potentially diminishing the desire for addictive substances, thereby reducing or eliminating the need for the addictive substance.

To date Verrian has developed:

  • PSI GEN and
  • PSI GEN+

These Psilocybin products are focused on opiate addiction reduction. As Natural Psilocybin extracts, from organically cultivated mushrooms, combined with metabolism enhancing natural herbs, they are ideal for individuals commencing micro-dosing and capable of being combined with additional anti-addiction therapies.

All of Verrian’s compounds are derived from organic, glyphosate free naturally occurring plants, grown specifically for its own purposes.

GOALS AND VISION

In addition to facility & equipment investments outlined above, the company has invested Cdn$2,400,000 worth of clinical trial design development and proprietary formulations into its psilocybin trademarked PSI-GEN formulations, and cannabis products, including trademarked CBDaily and CBNight.

Verrian’s world renowned addiction medicine experts are moving ahead to develop new potential treatments for therapy, with rigorous clinical research. Once EU GMP & narcotics handling recertification are secured, capabilities will extend to:

  • Specialty Pharma – Custom formulations
  • Psilocybin Refinement & Production – For micro dosing

“I am extremely excited at the opportunity to acquire an established Psychedelic medicine company in Europe. As an innovative company, Mota always seeks to be a leader in the natural health space and we see the psychedelic medicine market becoming a major part of the industry. This acquisition allows us to have first mover advantage in the Psychedelic market, and Mota’s existing distribution network will be ready to capitalize on the opportunity once regulation has been put in place,” stated Ryan Hoggan, CEO of the Company.

The Letter of Intent contemplates that the Company would acquire all of the outstanding share capital of Verrian in consideration for Cdn$21,100,000, of which Cdn$20,000,000 will be satisfied through the issuance of common shares (the “Consideration Shares“) to the existing shareholders of Verrian, and the balance will be payable in cash to retire certain outstanding shareholder loans due and owing by Verrian. The Consideration Shares will be subject to the terms of a thirty-six month time release pooling arrangement, during which time they may not be transferred, assigned, pledged or otherwise traded.

Readers are cautioned that the Letter of Intent entered into with Verrian does not set forth the final terms of the Proposed Transaction, nor have such terms been finalized. Any consideration offered to acquire Verrian remains subject to the results of ongoing due diligence. Completion of the Proposed Transaction is subject to a number of conditions, including, not limited to, completion of due diligence, negotiation of definitive documentation, and the receipt of any required regulatory approvals. The Proposed Transaction cannot be completed until these conditions are satisfied and there can be no assurance that the Proposed Transaction will be completed at all.

The Proposed Transaction is not expected to constitute a fundamental change for the Company, nor is it expected to result in a change of control of the Company, within the meaning of applicable securities laws and the policies of the Canadian Securities Exchange. The Company will provide further information regarding its review of Verrian, and the Proposed Transaction, as that information becomes available.

About Mota Ventures Corp.

Mota Ventures is an established eCommerce, direct to consumer provider of a wide range of CBD products in the United States and Europe. In the United States, the company sells a CBD hemp-oil formulation derived from hemp grown and formulated in the US through its Nature’s Exclusive brand. Within Europe, its Sativida brand of award winning 100% organic CBD oils and cosmetics are sold throughout Spain, Portugal, Austria, Germany, France, and the United Kingdom. Mota Ventures is also seeking to acquire additional revenue producing CBD brands and operations in both Europe and North America, with the goal of establishing an international distribution network for CBD products. Low cost production, coupled with international, direct to customer, sales channels will provide the foundation for the success of Mota Ventures.

ON BEHALF OF THE BOARD OF DIRECTORS

MOTA VENTURES CORP.

Ryan Hoggan
Chief Executive Officer

For further information, readers are encouraged to contact Joel Shacker, President at +604.423.4733 or by email at [email protected] or www.motaventuresco.com

Hollister Biosciences $HOLL.ca Closes Acquisition of AlphaMind Brands Inc. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:15 AM on Thursday, April 30th, 2020
  • Company has now closed its acquisition of AlphaMind Brands Inc., a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products
  • Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction

VANCOUVER, April 30, 2020 - Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that further to the signing of the definitive agreement, as amended (the “SEA“), the Company has now closed its acquisition of AlphaMind Brands Inc. (“AlphaMind“), a growth stage company, that is developing a portfolio of certified legal mushroom based natural health products (the “Transaction“).

“We are very pleased to close our acquisition of AlphaMind”, shared Carl Saling, Founder and CEO of Hollister.  “It is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.  We are excited to bring another promising brand under the Hollister umbrella, especially in such a fast growing and exciting sector.”

“We are very pleased to have closed this transaction”, shared Dr. Nikos C. Apostolopoulos, Chief Product & Research Officer of Alphamind Brands.  “We are looking forward to working with Hollister to build out our medicinal mushroom based product line and conducting further R&D to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments.”

Key Terms of The Transaction

Pursuant to the terms of the SEA, the Company has acquired AlphaMind for consideration of CDN$1,200,000 which is being satisfied by the issuance of 4,200,000 Hollister common shares (the “Payment Shares“) on the Closing Date pro rata to the shareholders of AlphaMind and an additional 1,800,000 common shares (the “Earn-Out Shares“) to be issued pro rata to the former shareholders of AlphaMind on the earlier of (i) AlphaMind meeting certain milestones (detailed below) or (ii) December 31st, 2021.

  • The Payment Shares and the Earn-Out Shares will be issued at a deemed value of $0.20 per share;
  • The Payment Shares are subject to certain voluntary hold periods as follows: 331/3% until May 30th, 2020; an additional 331/3% until June 30th, 2020; and the remaining 331/3% until August 30th, 2020;
  • The Earn-Out Shares will be issued on the earlier of (i) December 31st, 2020, or (ii) upon AlphaMind’s first production run or its first sales of product.

Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Transaction.

About AlphaMind Brands Inc.

Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate. 

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Transaction and has neither approved nor disapproved the contents of this press release.

The securities to be issued in connection with the Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

View original content to download multimedia:http://www.prnewswire.com/news-releases/hollister-biosciences-closes-acquisition-of-alphamind-brands-inc-301049911.html

MUST WATCH INTERVIEW OF THE YEAR – Empower Clinics $CBDT.ca Closes Up 77% On 25M Shares. This Is Why … And This Is Where It Is Going $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 9:47 PM on Monday, April 27th, 2020

With 165,000 patients, Empower Clinics (CBDT:CSE) (EPWCF:OTCQB) has a database that almost every medical cannabis and CBD company would kill for.  Patient visits increased 800% in February. 590% in March and 480% for Q1. 

More importantly, it is the only small cap company on the continent (that we know of) that is capable of launching COVID-19 Antibody Testing for individuals and businesses nationwide.  Why?  Because its simply not enough to be able to get your hands on some test kits.  The real challenge is having the infrastructure in place to test people in clinics, via drive though and in the workplace.    

It’s pretty much a military precision process that few small cap CEO’s could handle.  

But Empower Clinics CEO, Steven McAuley, is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch. We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never …. which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth.  

And now he’s set his sights on Antibody Testing.  He’s not just looking, he’s already started.  

Forget NetFlix Tonight.  Watch this.

Empower Clinics $CBDT.ca Commences Corona Virus #Covid19 Antibody Testing and Establishes National Rollout Plan and Signs Supply Agreements for Rapid Covid-19 $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:18 AM on Monday, April 27th, 2020
  • Empower is utilizing clinic operations and tele-medicine to provide COVID-19 antibody testing to patients and consumers,
  • Establishes a four-phase nationwide rollout of Rapid COVID-19 testing and signs new COVID-19 test supply agreements

VANCOUVER, BC / April 27, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(OTCQB:EPWCF)(Frankfurt:8EC) (“Empower” or the “Company”), a vertically integrated life sciences company is pleased to announce it has commenced COVID-19 antibody testing in its Sun Valley Health clinics in Phoenix, AZ using a blood draw test by clinic phlebotomists that are sent to an COVID-19 FDA approved laboratory partner. The laboratory submitted its request for FDA approval on March 16, 2020 under the Emergency Use Authorization (EUA).

“The Company has established a four-phase national COVID-19 testing program utilizing Rapid COVID-19 test kits”, said Steven McAuley, Chairman & CEO of Empower.

Phase One Testing in-clinics in Arizona, utilizing a patient blood draw by clinic phlebotomists, then samples are sent to our laboratory test partner for analysis, with test results expected within 48 hours.

Phase Two Offering a Rapid COVID-19 antibody test with results in 1-15 minutes. The service will be offered in-clinics using a drive-up service, conducted by Company clinic staff. In addition, an outbound door-step service, to support a variety of consumer, patient and community needs will be offered using certified mobile technicians. The Company anticipates phase two services will commence in May 2020.

Phase Three Business Employee Testing (BET) programs, offering Rapid COVID-19 testing to businesses on a one-time basis, repeat basis and/or subscription basis, to assist businesses to get back to work safely, will be offered. The Company anticipates phase three services will commence in May 2020.

Phase Four U.S. nationwide roll-out, offering all phases of Company services, that can be accessed online at Company websites and call centers, to purchase Rapid COVID-19 test kits. The Company anticipates phase four services to commence in Q3 2020.

Steven McAuley further states, “Our team are ready to meet the crisis head on, and we have ensured that the test processes and the test kits we use, are approved in the United States under the Emergency Use Authorization (EUA), as defined by the U.S. Food and Drug Administration (FDA).”

The Company has secured test kit supply agreements with two suppliers, NanoID Technologies Pty Ltd., that supply Zhuhai Livzon Diagnostics Inc. Rapid test kits, who made their test kit submission to the FDA on April 16th, 2020, and Emunah Trust, LLC, that supply Hangzhou TestSea Biotechnology Co., Ltd., Rapid test kits, who made their Rapid COVID-19 test kit submission to the FDA on April 16th, 2020.

CNN’s Dr. Sanjay Gupta explains what the science behind that testing means. Source: CNN

https://www.cnn.com/videos/health/2020/04/10/antibody-tests-fauci-week-or-so-gupta-dnt-lead-vpx.cnn

The World Health Organization, Director-General Dr. Tedros Adhanom Ghebreyesus has said, “Make no mistake: we have a long way to go. This virus will be with us for a long time. He has further stated, “We have a simple message for all counties: test, test, test.”

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options. The Company now offers COVID-19 testing options and physician- based consultations, to address COVID-19 concerns.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

Chairman & CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

720-352-1398

[email protected]

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond; the ability of the Company to complete or execute phases One, Two, Three or Four as noted above, and Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Steven J. McAuley
Chief Executive Officer
EMPOWER | www.empowerclinics.com
(604) 789-2146 | @stevenmcauley
[email protected]

Hollister Biosciences $HOLL.ca Enters Into Definitive Agreement to Acquire AlphaMind Brands Inc. $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca $FAF.ca

Posted by AGORACOM-JC at 8:20 AM on Thursday, April 23rd, 2020
  • Entered into a share exchange agreement dated April 22nd, 2020 among the Company, AlphaMind Brands Inc. and the shareholders of TargetCo
  • Alphamind Brands is developing a portfolio of certified legal mushroom based natural health products
  • The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate.

VANCOUVER, April 23, 2020 – Hollister Biosciences Inc. (CSE: HOLL, FRANKFURT: HOB, OTC: HSTRF) (the “Company” or “Hollister“) – a diversified cannabis branding company with products in over 220 dispensaries throughout California, is pleased to announce that it has entered into a share exchange agreement dated April 22nd, 2020 among the Company, AlphaMind Brands Inc. (“TargetCo“) and the shareholders of TargetCo (the “Definitive Agreement“), pursuant to which, the Company will acquire all of the issued and outstanding shares of TargetCo (the “Proposed Transaction“).  

Alphamind Brands is a Canada and US based growth stage company, that is developing a portfolio of certified legal mushroom based natural health products. It is also actively conducting R&D initiatives, led by Dr. Nikos C. Apostolopoulos, who is exploring psilocybin based pharmaceutical treatments.  The company’s “ready to ship” product SKU’s include Cordyceps, Lion’s Mane, Shiitake, Oyster and Reishi Mushroom based: liquid tinctures, concentrated mushroom powder(s), teas, and chocolate. 

“We are very pleased to have completed the next step in consummating this very exciting acquisition”, shared Carl Saling, Founder and CEO of Hollister Biosciences, Inc.  “It is a fundamental value of our company to improve the overall health and performance of our customers through our high-quality products and the health benefits associated with medicinal mushrooms are tremendous.  Not to mention, it is our continual objective to broaden our product scope and Alphamind, with its experienced management team, is a perfect foothold for us in the fast-growing market for medicinal mushrooms and complements our existing cannabis and hemp-based product offering.”

“I think we have found a great partner in Hollister”, shared Robert Birmingham, CEO of Alphamind Brands.  “We have medicinal mushroom based product SKU’s ready to ship and R&D is underway to develop an exciting IP portfolio surrounding psilocybin based pharmaceutical treatments. Being under the Hollister umbrella will allow us to access additional markets and leverage their existing manufacturing and distribution infrastructure and will be a fundamental part of the future growth of our business.”

The Proposed Transaction

Pursuant to the terms of the Definitive Agreement, Hollister will acquire all of the issued and outstanding securities of TargetCo in consideration for the issuance of 6,000,000 common shares of the Company (the “Payment Shares“) pro rata to shareholders of TargetCo at a deemed price of $0.20 per Payment Share upon closing of the Proposed Transaction (the “Closing Date“).

The Proposed Transaction remains subject to certain closing conditions including, without limitation, (a) the receipt by Hollister of any necessary corporate and regulatory approval; and (b) each party’s representations and warranties in the Definitive Agreement being true and correct in all aspects as of the Closing Date, and each party meeting its terms and conditions and completing its covenants and obligations as contained therein. There can be no guarantees that the Proposed Transaction will be completed as contemplated or at all.

Hollister will not be assuming any long-term debt; no new control position will be created and there is no change in management or the Board of Directors of Hollister in connection with the Proposed Transaction.

In addition, the Company also reports that it will issue 500,000 common shares at a deemed price of $0.12 per share to an arm’s length consultant pursuant to a consulting agreement in which services were provided from December 1, 2019 to the date hereof.  In addition, the Company will issue 90,400 shares to an arm’s length consultant pursuant to a consulting agreement in which services have been rendered since February 17, 2020 (See press release dated February 25th, 2020).  All shares issued pursuant to the consulting agreements will be subject to a four month and a day hold period from the date of issuance.

About Hollister Biosciences Inc.

Hollister Biosciences Inc. is a multi-state cannabis company with a vision to be the sought-after premium brand portfolio of innovative, high-quality cannabis & hemp products. Hollister uses a high margin model, controlling the whole process from manufacture to sales to distribution or seed to shelf. Products from Hollister Biosciences Inc. include HashBone, the brand’s premier artisanal hash-infused pre-roll, along with concentrates (shatter, budder, crumble), distillates, solvent-free bubble hash, pre-packaged flower, pre-rolls, tinctures, vape products, and full-spectrum high CBD pet tinctures. Hollister Cannabis Co. additionally offers white-labeling manufacturing of cannabis products.  Our wholly-owned California subsidiary Hollister Cannabis Co is the 1st state and locally licensed cannabis company in the city of Hollister, CA birthplace of the “American Biker”.

Website: www.hollistercannabisco.com

ON BEHALF OF THE BOARD

“Carl Saling”

CEO and Director

The CSE does not accept responsibility for the adequacy or accuracy of this release.

The CSE has not in any way passed upon the merits of the Proposed Transaction and has neither approved nor disapproved the contents of this press release.

The securities to be issued in connection with the Proposed Transaction have not been and will not be registered under the U.S. Securities Act of 1933, as amended (the “1933 Act“), or under any state securities laws, and may not be offered or sold, directly or indirectly, or delivered within the United States or to, or for the account or benefit of, U.S. persons (as defined in Regulation S under the 1933 Act) absent registration or an applicable exemption from the registration requirements. This news release does not constitute an offer to sell or a solicitation to buy such securities in the United States.

This news release may include forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

Empower Clinics $CBDT.ca Continues to Advance Development of #Psilocybin and Psychedelics Division to Address Significant Mental Health Issues $WEED.ca $CGC $ACB $APH $CRON.ca $OGI.ca

Posted by AGORACOM-JC at 7:20 AM on Wednesday, April 22nd, 2020

Empower is utilizing clinics, physicians, technology and direct access to 165,000 patients to launch dedicated division and resources for psilocybin research.

  • Created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder and addiction
  • “Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic.” said Steven McAuley, Chairman & CEO of Empower

VANCOUVER, BC / April 22, 2020 / EMPOWER CLINICS INC. (CSE: CBDT)(OTC: EPWCF)(Frankfurt 8EC) (“Empower” or the “Company”), a vertically integrated and growth-oriented life sciences company is pleased to announce, it is has created a subsidiary company dedicated to the advancement of psilocybin research and patient care, addressing the significant mental health issues of anxiety, depression, post-traumatic stress disorder (PTSD) and addiction.

The Company is leveraging its assets that include the existing clinic network, the developing franchise brand, tele-medicine, access to its 165,000 patients and large physician team, to make advancements in psilocybin research and psychedelics therapy in general.

“Mental health conditions such as anxiety, depression, addiction and PTSD appear to be on the rise with the onset of the Coronavirus pandemic.” said Steven McAuley, Chairman & CEO of Empower. “Clinical trials continue to show that psilocybin therapies may provide tremendous help with these conditions, that we see every day in our clinics. As a Company, we must endeavour to utilize our assets and capabilities to positively impact patients’ lives.”

The mental health crisis could cost the world $16 trillion by 2030 according to Future Market Insights and further, the global behavioral health (non-pharmacological) market is expected to be valued at US$156 billion by 2028.

According to the World Health Organization (WHO), depression is the leading cause of disability worldwide, and it is a major contributor to the overall global burden of disease.

The United States Food and Drug Administration has determined that preliminary clinical evidence indicates psilocybin may demonstrate substantial improvement over other available therapies for treatment-resistant depression; and granted a Breakthrough Therapy designation for a treatment that uses psilocybin as a therapy for such depression.

ABOUT EMPOWER

Empower is a vertically integrated health & wellness brand with a network of corporate and franchised health & wellness clinics in the U.S. The Company is building its first hemp-derived CBD extraction facility and produces its proprietary line of cannabidiol (CBD) based products. The company is a leading multi-state operator of a network of physician-staffed wellness clinics, focused on helping patients improve and protect their health, through innovative physician recommended treatment options. The Company has commenced activity on how to connect its significant data, to the potential of the efficacy of alternative treatment options related to hemp-derived cannabidiol (CBD) therapies, psilocybin and other psychedelic plant-based treatment options.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Steven McAuley

CEO

[email protected]

604-789-2146

Investors: Dustin Klein

SVP, Business Development

[email protected]

720-352-1398

For French inquiries: Remy Scalabrini, Maricom Inc., E: [email protected], T: (888) 585-MARI

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release. Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include statements regarding; the Company’s intention to create psilocybin and psychedelics divisions, that market research on advancements in psilocybin and psychedelics in North America and globally will create greater shareholder value, the Company’s intention to open a hemp-based CBD extraction facility, the expected benefits to the Company and its shareholders as a result of the proposed acquisitions and partnerships; the effectiveness of the extraction technology; the expected benefits for Empower’s patient base and customers; the benefits of CBD based products; the effect of the approval of the Farm Bill; the growth of the Company’s patient list and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2019 and beyond. Psychedelic substances remain illegal in most countries, so please reference your local laws in relation to medical or recreational use. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including; that the Company may not open a hemp-based CBD extraction facility; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed acquisitions and partnerships; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.